Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy.
Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy.
复制标题
识别 MicroRNA 通路变异作为免疫治疗患者选择的生物标志物。
DOI：
10.1007/978-1-4939-9773-2_9
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Weidhaas,JoanneB
中科院分区：
文献类型：
--
作者：
Weidhaas,JoanneB
在本章中，我们讨论了microRNA （miRNA）相关生殖系生物标志物的发现和验证，以及它们在免疫治疗患者队列中的应用，以预测反应和毒性。mirna是发现的第一类非编码rna，这些途径已被证明是系统应激反应的重要调节因子，包括对癌症治疗的应激反应。我们详细介绍了鉴定破坏miRNA电路的生殖系生物标志物的原始发现工作，然后介绍了这些生物标志物的选择、应用和验证，以及它们预测检查点治疗重要结果的潜力。
In this chapter we discuss the discovery and validation of microRNA (miRNA) associated germline biomarkers, as well as their application on a cohort of patients treated with immune therapy to predict response and toxicity. MiRNAs are the first class of noncoding RNAs discovered, and these pathways have been shown to be important regulators of the systemic stress response, including that to cancer therapy. We detail the original discovery efforts identifying germline biomarkers that disrupt miRNA circuitry, and then the selection, application, and validation of these biomarkers and their potential to predict important outcomes to checkpoint therapy.